New combo therapy aims to stop breast cancer return
NCT ID NCT05996107
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing whether the drug ribociclib (Kisqali) can be safely given alongside standard radiation therapy after surgery for women with a high-risk type of breast cancer (HR+/HER2-). About 30 participants will take ribociclib daily for up to 6 weeks while receiving radiation. The main goal is to find the safest dose and watch for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ribociclib (Kisqali) plus radiation therapy
What this could lead to
If successful, this could show that adding ribociclib to standard radiation is safe and may help prevent breast cancer from coming back in high-risk patients.
What could go wrong
This is a very early phase 1 trial with only 30 people, so it is mainly checking safety and the right dose. It is too small to prove if the combination actually works better than radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHCMC Seidman Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan Health West
RECRUITINGWyoming, Michigan, 49519, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••